<p>WuXi Biologics (Cayman) Inc. announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated for the development of an innovative trispecific T-cell Engager for the treatment of B-cell mediated autoimmune diseases. This agreement provides Vertex with access to WuXi Biologics’ research and development capabilities to support the advancement of this molecule. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via CNW (Ref. ID: C1701) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>WuXi Biologics (Cayman) Inc. has signed a license and research service agreement with Vertex Pharmaceuticals for the development of a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases. This partnership allows Vertex to utilize WuXi Biologics’ R&D capabilities to advance this innovative molecule.</p>

Reuters

VanEck Biotech ETF

ALPS Medical Breakthrough

WuXi Biologics

Vertex Pharma

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares US Pharma

VG Health

iShares Biotechnology ETF

Health Care Select Sector SPDR

Minsheng Royal CSI Biotechnology Theme ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

ChinaAMC CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bear 3X

China Southern Hang Seng Biotech ETF(QDII)

Proshares Ultra Nasdaq Biotech

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ark Genomic Revolution ETF

China Merchants CSI Biotechnology Theme ETF

WUXI BIO

E Fund CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

WuXi Biologics Signs License and Research Service Agreement with Vertex Pharmaceuticals